What's Happening?
FUJIFILM Biosciences has introduced BalanCD HEK293 Perfusion A, a new medium designed to optimize gene therapy production. This medium utilizes suspension HEK293 cells and perfusion technology to efficiently produce viral vectors necessary for gene therapies. It supports various applications, including viral vector production and recombinant protein production, by maximizing cell growth and productivity. The medium is compatible with different transfection methods and is suited for both steady-state and intensified perfusion processes, offering scalability and consistent quality for gene therapy development.
Why It's Important?
The introduction of BalanCD HEK293 Perfusion A is significant for the gene therapy industry, as it provides a reliable and scalable solution for producing viral vectors. This advancement can reduce capital expenditures associated with gene therapy production, making it more accessible and efficient. By enhancing the production process, FUJIFILM Biosciences is contributing to the development of innovative treatments and therapies, potentially benefiting patients by increasing the availability and quality of gene therapies.
What's Next?
FUJIFILM Biosciences aims to continue supporting the gene therapy industry by providing high-quality resources and solutions. The company plans to expand its portfolio of gene therapy application solutions, further optimizing production processes and enhancing the scalability of gene therapies. This initiative is expected to facilitate the development of advanced therapies and increase their availability to patients.
